Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
PEN's Cash to Debt is ranked higher than
76% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. PEN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PEN' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: No Debt
Current: No Debt

Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6679
N/A
No Debt
Equity to Asset 0.87
PEN's Equity to Asset is ranked higher than
87% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. PEN: 0.87 )
Ranked among companies with meaningful Equity to Asset only.
PEN' s Equity to Asset Range Over the Past 10 Years
Min: -0.1  Med: 0.87 Max: 0.88
Current: 0.87
-0.1
0.88
Z-Score: 31.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 0.99
PEN's Operating margin (%) is ranked lower than
54% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 2.65 vs. PEN: 0.99 )
Ranked among companies with meaningful Operating margin (%) only.
PEN' s Operating margin (%) Range Over the Past 10 Years
Min: -1.27  Med: 2.25 Max: 2.4
Current: 0.99
-1.27
2.4
Net-margin (%) 0.31
PEN's Net-margin (%) is ranked lower than
52% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.06 vs. PEN: 0.31 )
Ranked among companies with meaningful Net-margin (%) only.
PEN' s Net-margin (%) Range Over the Past 10 Years
Min: 1.27  Med: 1.79 Max: 4.61
Current: 0.31
1.27
4.61
ROE (%) 0.89
PEN's ROE (%) is ranked lower than
52% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. PEN: 0.89 )
Ranked among companies with meaningful ROE (%) only.
PEN' s ROE (%) Range Over the Past 10 Years
Min: 0.98  Med: 0.98 Max: 0.98
Current: 0.89
ROA (%) 0.35
PEN's ROA (%) is ranked higher than
51% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: -0.01 vs. PEN: 0.35 )
Ranked among companies with meaningful ROA (%) only.
PEN' s ROA (%) Range Over the Past 10 Years
Min: 1.23  Med: 2.33 Max: 5.76
Current: 0.35
1.23
5.76
ROC (Joel Greenblatt) (%) 3.44
PEN's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 4.93 vs. PEN: 3.44 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PEN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3.24  Med: 6.71 Max: 7.26
Current: 3.44
-3.24
7.26
» PEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

PEN Guru Trades in

Q3 2015

PEN Guru Trades in Q3 2015

Paul Tudor Jones 6,700 sh (New)
PRIMECAP Management 100,000 sh (New)
Chuck Royce 1,000 sh (New)
RS Investment Management 115,701 sh (New)
» More
Q4 2015

PEN Guru Trades in Q4 2015

PRIMECAP Management 101,300 sh (+1.30%)
Chuck Royce 1,000 sh (unchged)
Paul Tudor Jones Sold Out
RS Investment Management Sold Out
» More
Q1 2016

PEN Guru Trades in Q1 2016

Chuck Royce 1,000 sh (unchged)
PRIMECAP Management 86,800 sh (-14.31%)
» More
» Details

Insider Trades

Latest Guru Trades with PEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:OTCPK:DRWKF, NAS:CYBX, NAS:WMGI, NYSE:NVRO, NAS:CNMD, OTCPK:IOBCF, NAS:BABY, NAS:ZLTQ, NAS:CYNO, NYSE:GMED, NAS:MASI, OTCPK:NHNKY, OTCPK:SHWGY, NAS:LDRH, NAS:INGN, NAS:HTWR, OTCPK:GGNDF, NYSE:ITGR, NAS:SPNC, NAS:OFIX » details
Traded in other countries:0P8.Germany,
Penumbra Inc designs, develops, manufactures and markets medical devices. The products of the company address ischemic stroke, hemorrhagic stroke and vascular conditions that can be treated through thrombectomy and embolization procedures.

Penumbra Inc was incorporated in 2004 as a Delaware corporation under the name Penumbra. It is an interventional therapies company that designs, develops, manufactures and markets medical devices. The products of the company address ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. The Company sells its products to hospitals through its salesforce, as well as through distributors. It sells its products through direct sales organization in the United States, Europe, Canada and Australia. Its products include Penumbra System, ACE, Penumbra Coil 400, Penumbra SMART COIL, LIBERTY Stent, Apollo System, Ruby Coil and Indigo System. The Company competes with manufacturers and distributors of neurovascular and peripheral vascular medical devices. Its competitors are Boston Scientific, Johnson & Johnson, Medtronic, Stryker and Terumo. Its products are medical devices subject to extensive and ongoing regulation by the FDA under the Federal Food, Drug, and Cosmetic Act (FD&C Act), and its implementing regulations, as well as other federal and state regulatory bodies in the United States and comparable authorities in other countries under other statutes and regulations.

Ratios

vs
industry
vs
history
P/E(ttm) 25.83
PEN's P/E(ttm) is ranked higher than
55% of the 171 Companies
in the Global Medical Devices industry.

( Industry Median: 28.44 vs. PEN: 25.83 )
Ranked among companies with meaningful P/E(ttm) only.
PEN' s P/E(ttm) Range Over the Past 10 Years
Min: 16.16  Med: 21.20 Max: 25.9
Current: 25.83
16.16
25.9
PE(NRI) 33.34
PEN's PE(NRI) is ranked lower than
60% of the 169 Companies
in the Global Medical Devices industry.

( Industry Median: 28.84 vs. PEN: 33.34 )
Ranked among companies with meaningful PE(NRI) only.
PEN' s PE(NRI) Range Over the Past 10 Years
Min: 21.04  Med: 27.48 Max: 33.46
Current: 33.34
21.04
33.46
P/B 7.80
PEN's P/B is ranked lower than
87% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 2.92 vs. PEN: 7.80 )
Ranked among companies with meaningful P/B only.
PEN' s P/B Range Over the Past 10 Years
Min: 4.83  Med: 6.33 Max: 7.82
Current: 7.8
4.83
7.82
P/S 4.91
PEN's P/S is ranked lower than
65% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 3.34 vs. PEN: 4.91 )
Ranked among companies with meaningful P/S only.
PEN' s P/S Range Over the Past 10 Years
Min: 3.48  Med: 4.19 Max: 5.21
Current: 4.91
3.48
5.21
EV-to-EBIT 844.92
PEN's EV-to-EBIT is ranked lower than
98% of the 170 Companies
in the Global Medical Devices industry.

( Industry Median: 22.47 vs. PEN: 844.92 )
Ranked among companies with meaningful EV-to-EBIT only.
PEN' s EV-to-EBIT Range Over the Past 10 Years
Min: 81.4  Med: 150.20 Max: 899.6
Current: 844.92
81.4
899.6
EV-to-EBITDA 430.06
PEN's EV-to-EBITDA is ranked lower than
100% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 18.29 vs. PEN: 430.06 )
Ranked among companies with meaningful EV-to-EBITDA only.
PEN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 52.7  Med: 105.80 Max: 457.9
Current: 430.06
52.7
457.9
Current Ratio 7.46
PEN's Current Ratio is ranked higher than
89% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.85 vs. PEN: 7.46 )
Ranked among companies with meaningful Current Ratio only.
PEN' s Current Ratio Range Over the Past 10 Years
Min: 4.4  Med: 7.46 Max: 8.81
Current: 7.46
4.4
8.81
Quick Ratio 5.51
PEN's Quick Ratio is ranked higher than
86% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.07 vs. PEN: 5.51 )
Ranked among companies with meaningful Quick Ratio only.
PEN' s Quick Ratio Range Over the Past 10 Years
Min: 2.75  Med: 5.51 Max: 7.03
Current: 5.51
2.75
7.03
Days Inventory 234.44
PEN's Days Inventory is ranked lower than
75% of the 278 Companies
in the Global Medical Devices industry.

( Industry Median: 134.88 vs. PEN: 234.44 )
Ranked among companies with meaningful Days Inventory only.
PEN' s Days Inventory Range Over the Past 10 Years
Min: 258.85  Med: 265.39 Max: 318.98
Current: 234.44
258.85
318.98
Days Sales Outstanding 55.46
PEN's Days Sales Outstanding is ranked higher than
69% of the 268 Companies
in the Global Medical Devices industry.

( Industry Median: 68.67 vs. PEN: 55.46 )
Ranked among companies with meaningful Days Sales Outstanding only.
PEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.71  Med: 55.00 Max: 57.75
Current: 55.46
53.71
57.75
Days Payable 21.64
PEN's Days Payable is ranked lower than
89% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 61.85 vs. PEN: 21.64 )
Ranked among companies with meaningful Days Payable only.
PEN' s Days Payable Range Over the Past 10 Years
Min: 15.1  Med: 15.46 Max: 20.09
Current: 21.64
15.1
20.09

Valuation & Return

vs
industry
vs
history
Price/Net Cash 17.26
PEN's Price/Net Cash is ranked lower than
52% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 16.44 vs. PEN: 17.26 )
Ranked among companies with meaningful Price/Net Cash only.
PEN' s Price/Net Cash Range Over the Past 10 Years
Min: 9.33  Med: 13.14 Max: 13.69
Current: 17.26
9.33
13.69
Price/Net Current Asset Value 8.57
PEN's Price/Net Current Asset Value is ranked lower than
59% of the 234 Companies
in the Global Medical Devices industry.

( Industry Median: 7.01 vs. PEN: 8.57 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PEN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 5.48  Med: 6.52 Max: 7.56
Current: 8.57
5.48
7.56
Price/Tangible Book 7.79
PEN's Price/Tangible Book is ranked lower than
75% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 3.88 vs. PEN: 7.79 )
Ranked among companies with meaningful Price/Tangible Book only.
PEN' s Price/Tangible Book Range Over the Past 10 Years
Min: 5.23  Med: 5.93 Max: 6.92
Current: 7.79
5.23
6.92
Price/Median PS Value 1.18
PEN's Price/Median PS Value is ranked lower than
59% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. PEN: 1.18 )
Ranked among companies with meaningful Price/Median PS Value only.
PEN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.9  Med: 0.99 Max: 1.07
Current: 1.18
0.9
1.07
Price/Graham Number 3.40
PEN's Price/Graham Number is ranked lower than
66% of the 145 Companies
in the Global Medical Devices industry.

( Industry Median: 2.36 vs. PEN: 3.40 )
Ranked among companies with meaningful Price/Graham Number only.
PEN' s Price/Graham Number Range Over the Past 10 Years
Min: 2.3  Med: 2.59 Max: 3.04
Current: 3.4
2.3
3.04
Earnings Yield (Greenblatt) (%) 0.10
PEN's Earnings Yield (Greenblatt) (%) is ranked lower than
52% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 0.40 vs. PEN: 0.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PEN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 0.70 Max: 1.2
Current: 0.1
0.1
1.2

More Statistics

Revenue (TTM) (Mil) $205.1
EPS (TTM) $ 2.34
Short Percentage of Float5.90%
52-Week Range $35.32 - 61.87
Shares Outstanding (Mil)30.70

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 240 289 342
EPS ($) -0.16 0.07 0.33
EPS w/o NRI ($) -0.16 0.07 0.33
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NYSE:PEN

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Penumbra Announces Key Events at Society of NeuroInterventional Surgery 2016 Meeting Jul 19 2016
Penumbra, Inc. Schedules Second Quarter 2016 Earnings Release and Conference Call for August 9, 2016... Jul 15 2016
Penumbra, Inc. to Present at the Canaccord Genuity 36th Annual Growth Conference Jul 15 2016
Penumbra, Inc. to Present at the Canaccord Genuity 36th Annual Growth Conference Jul 15 2016
Penumbra, Inc. Schedules Second Quarter 2016 Earnings Release and Conference Call for August 9, 2016... Jul 15 2016
Why Penumbra (PEN) Could Be Positioned for a Surge? Jun 13 2016
The 20 highest-paid Bay Area executives under 40 in 2016 Jun 09 2016
PENUMBRA INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 09 2016
Penumbra (PEN) in Focus: Stock Adds 5.5% in Session Jun 07 2016
Redmile Group Sticking With Healthcare Picks After Rough Q1 Jun 03 2016
ETF’s with exposure to Penumbra, Inc. : May 27, 2016 May 26 2016
Penumbra, Inc. breached its 50 day moving average in a Bullish Manner : PEN-US : May 23, 2016 May 23 2016
PENUMBRA INC Financials May 18 2016
Penumbra, Inc. :PEN-US: Earnings Analysis: Q1, 2016 By the Numbers May 17 2016
ETF’s with exposure to Penumbra, Inc. : May 16, 2016 May 16 2016
Penumbra, Inc. breached its 50 day moving average in a Bearish Manner : PEN-US : May 13, 2016 May 13 2016
Penumbra (PEN) Q1 Earnings & Revenues Beat Expectations May 10 2016
Edited Transcript of PEN earnings conference call or presentation 9-May-16 8:30pm GMT May 09 2016
Penumbra posts 1Q profit May 09 2016
Penumbra posts 1Q profit May 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)